Ocuvex Drug Patent Portfolio
Ocuvex owns 1 orange book drug protected by 13 US patents Given below is the list of Ocuvex's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11666563 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | 16 Jul, 2039 | Active |
| US12290511 | Pharmaceutical Preparation Containing Pyridyl Aminoacetic Acid Compound | 27 Dec, 2038 | Active |
| US10774072 | Crystal of N-substituted sulfonamide compound | 10 Jun, 2035 | Active |
| US10179127 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | 08 Jan, 2035 | Active |
| US10702511 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | 08 Jan, 2035 | Active |
| US10765750 | Pharmaceutical composition containing pyridylaminoacetic acid compound | 08 Jan, 2035 | Active |
| US11197849 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | 08 Jan, 2035 | Active |
| US11793798 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | 08 Jan, 2035 | Active |
| US12295946 | Pharmaceutical Formulations Comprising A Pyridylaminoacetic Acid Compound | 08 Jan, 2035 | Active |
| US9415038 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | 08 Jan, 2035 | Active |
| USRE48183 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | 08 Jan, 2035 | Active |
| US8648097 | Pyridylaminoacetic acid compound | 13 Oct, 2029 | Active |
| US8685986 | Medical composition for treatment or prophylaxis of glaucoma | 13 Oct, 2029 | Active |
Latest Legal Activities on Ocuvex's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ocuvex.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Jul, 2025 | US8648097 |
| Paralegal Petition Decision | 26 Jun, 2025 | US8648097 |
| Paralegal Petition Decision | 26 Jun, 2025 | US10702511 |
| Paralegal Petition Decision | 26 Jun, 2025 | US8685986 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 May, 2025 | US11197849 |
| FDA Final Eligibility Letter | 20 May, 2025 | US10702511 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8648097 |
| FDA Final Eligibility Letter | 20 May, 2025 | US8685986 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US10702511 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US8685986 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US8648097 |
| Recordation of Patent Grant Mailed | 20 May, 2025 | US12295946 |
| Mail Patent eGrant Notification | 13 May, 2025 | US12295946 |
| Patent eGrant Notification | 13 May, 2025 | US12295946 |
| Email Notification | 13 May, 2025 | US12295946 |
Ocuvex's Family Patents
Ocuvex drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 15.6% of its total global patent coverage. Click
below to unlock the full patent family tree.
Ocuvex Drug List
Given below is the complete list of Ocuvex's drugs and the patents protecting them.
1. Omlonti
Omlonti is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11666563 | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
16 Jul, 2039
(13 years from now)
| Active |
| US12290511 | Pharmaceutical Preparation Containing Pyridyl Aminoacetic Acid Compound |
27 Dec, 2038
(12 years from now)
| Active |
| US10774072 | Crystal of N-substituted sulfonamide compound |
10 Jun, 2035
(9 years from now)
| Active |
| US10179127 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
08 Jan, 2035
(8 years from now)
| Active |
| US10702511 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
08 Jan, 2035
(8 years from now)
| Active |
| US10765750 | Pharmaceutical composition containing pyridylaminoacetic acid compound |
08 Jan, 2035
(8 years from now)
| Active |
| US11197849 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
08 Jan, 2035
(8 years from now)
| Active |
| US11793798 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
08 Jan, 2035
(8 years from now)
| Active |
| US12295946 | Pharmaceutical Formulations Comprising A Pyridylaminoacetic Acid Compound |
08 Jan, 2035
(8 years from now)
| Active |
| US9415038 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
08 Jan, 2035
(8 years from now)
| Active |
| USRE48183 | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
08 Jan, 2035
(8 years from now)
| Active |
| US8648097 | Pyridylaminoacetic acid compound |
13 Oct, 2029
(3 years from now)
| Active |
| US8685986 | Medical composition for treatment or prophylaxis of glaucoma |
13 Oct, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omlonti's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List